Skip to main content
Caplight Logo









Treos Bio

Treos Bio

Private
LondonHealthcare & Life Scienceshttps://www.treosbio.com/

Last Round

VC Round

Aug 27, 2025

Total Funding Raised

$42M

Company Overview

Treos Bio is a biotechnology company that develops precision peptide cancer immunotherapies and companion diagnostic tests using its proprietary computational technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

cancer immunotherapypeptide-based immunotherapyprecision medicinecompanion diagnosticsepitope selectioncomputational drug discoverycancer vaccinebiomarker testingHLA genotypingoncology biotechAI drug discoveryin silico drug designpersonalized cancer treatmentneoantigen predictionclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Treos Bio Comparables

Compare Treos Bio with similar companies based on industry and business-model similarity.

Treos Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Geneos Therapeutics
79%
Scancell Holdings Plc
76%
Gritstone bio
76%

Treos Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundAug 27, 2025
Convertible DebtMar 31, 2021
Series AFeb 13, 2017

Key People

Founding team and executive leadership

Christopher Gallen

Executive Chairman, Chairman and CEO, Treos Bio Ltd

Executive Team

Sunjeet S.

Chief Executive Officer Board Member

Executive Team

Treos Bio Investors

Notable investors and investment history

Treos Bio investors
InvestorRounds
BXR GroupSeries A
Luminous VenturesConvertible Debt
Outsized VenturesConvertible Debt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 27, 2025

    $2.1M round raised

  • Feb 13, 2017

    $28M round led by BXR Group

Treos Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Treos Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Treos Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Employee Range16
Year Founded2017
Last FundingAug 27, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?